Metastatic renal cell carcinoma management

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Understanding the molecular basis of renal cell carcinoma (RCC), particularly its genetic and angiogenic factors, has advanced significantly.
• The study of von Hippel-Lindau disease has been pivotal in unraveling RCC's molecular underpinnings.

Purpose of the Study:

• To evaluate current medical treatment strategies for metastatic renal cell carcinoma (mRCC).
• To review novel systemic therapies and their impact on mRCC patient outcomes.

Main Methods:

• Literature search of recent publications using PubMed with keywords: advanced and metastatic renal cell carcinoma, anti-angiogenesis drugs, and systemic therapy.
• Inclusion of significant meeting abstracts to ensure comprehensive coverage of the latest research.

Main Results:

• Targeted therapies like sunitinib, sorafenib, and bevacizumab have demonstrated increased progression-free survival compared to cytokine therapy.
• Temsirolimus has shown improved overall survival in high-risk mRCC patients.
• Potential future therapeutic targets include growth factors and enzymes like carbonic anhydrase IX.

Conclusions:

• Advances in clear cell carcinoma molecular biology herald a new era in mRCC therapy.
• Novel agents have become standard of care, with sunitinib recognized as the first-line treatment.
• Despite progress, complete responses remain rare, and critical issues in managing mRCC require further investigation.